title: Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens.
abstract: The incidence of muscle pains and changes in serum concentrations of potassium, calcium and creatine kinase following suxamethonium were investigated after no pretreatment or pretreatment with intravenous tubocurarine 0.05 mg.kg-1, intravenous chlorpromazine 0.1 mg.kg-1, alphatocopherol (vitamin E) 600 mg in three divided doses orally, aspirin 600 mg orally or intravenous calcium chloride 5 mg.kg-1 in groups of 20 patients each. The incidence of myalgia was reduced significantly by tubocurarine, chlorpromazine and alphatocopherol. However, the increase in creatine kinase was attenuated only in the groups of patients who received tubocurarine and chlorpromazine. The changes in serum potassium and calcium concentrations were within acceptable limits. The intubating conditions were not as good in the patients who received tubocurarine as in the other groups. Effectiveness of chlorpromazine in preventing both the myalgia and the biochemical changes suggests the involvement of phospholipases in the pathogenesis of suxamethonium-induced muscle damage.
authors.affiliation: Department of Anaesthetics, Queens University, Belfast.
authors.forename: C
authors.initials: C
authors.lastname: McLoughlin
authors.forename: P
authors.initials: P
authors.lastname: Elliott
authors.forename: G
authors.initials: G
authors.lastname: McCarthy
authors.forename: R K
authors.initials: RK
authors.lastname: Mirakhur
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D002122:Calcium Chloride / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007442:Intubation, Intratracheal; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D010146:Pain / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D011188:Potassium / Q000097:blood; D011292:Premedication; D013390:Succinylcholine / Q000009:adverse effects*; D014403:Tubocurarine / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D014810:Vitamin E; D003402:Creatine Kinase; D013390:Succinylcholine; D002122:Calcium Chloride; D001241:Aspirin; D011188:Potassium; D002118:Calcium; D002746:Chlorpromazine; D014403:Tubocurarine